Yuting Liu

PhD Student, ExPath


Yale Univerity


New drugs targeting Programmed Death Protein 1 and its ligand PD-L1 has shown promising therapeutic effect on cancer patients in recent 15 years. However, PD-L2 as another ligand of PD-1, is not well identified. In order to learn more about this ligand, how it’s regulated and its potential as a immunotherapy target must be studied.


Education & Training

BS Fudan University, Bachelor of Medicine (2014)

Contact Info

Yuting Liu